478 related articles for article (PubMed ID: 25812489)
1. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression.
Söderlund C; Rådegran G
Transplant Rev (Orlando); 2015 Jul; 29(3):181-9. PubMed ID: 25812489
[TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
4. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
6. Minimization of immunosuppression: transplant immunology.
Patel J; Kobashigawa JA
Transpl Immunol; 2008 Nov; 20(1-2):48-54. PubMed ID: 18930138
[TBL] [Abstract][Full Text] [Related]
7. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
[TBL] [Abstract][Full Text] [Related]
8. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression for heart transplantation: where are we now?
Kobashigawa JA; Patel JK
Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):203-12. PubMed ID: 16568129
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
12. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
Kaczmarek I; Ertl B; Schmauss D; Sadoni S; Knez A; Daebritz S; Meiser B; Reichart B
J Heart Lung Transplant; 2006 May; 25(5):550-6. PubMed ID: 16678034
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive therapy after human lung transplantation.
Knoop C; Haverich A; Fischer S
Eur Respir J; 2004 Jan; 23(1):159-71. PubMed ID: 14738248
[TBL] [Abstract][Full Text] [Related]
14. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant.
Opelz G; Döhler B
Transplantation; 2008 Aug; 86(3):371-6. PubMed ID: 18698238
[TBL] [Abstract][Full Text] [Related]
15. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
18. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
